Ceftriaxone-bilirubin-albumin interactions in the neonate: An in vivo study

Abstract

The in vivo bilirubin-albumin binding interaction of ceftriaxone (CRO) was investigated in 14 nonjaundiced newborns, aged 33–42 weeks of gestation, during the first few days of life after they had reached stable clinical condition. CRO (50 mg/kg) was infused intravenously over 30 min. The competitive binding effect of CRO on the bilirubin-albumin complex was estimated by determining the reserve albumin concentration (RAC) at baseline, at the end of CRO infusion, and at 15 and 60 min thereafter. Immediately after the end of drug administration, RAC decreased from 91.9 (±25.1) μmol/l to 38.6 (±10.1) μmol/l (P=0.0001). At the same time the plasma bilirubin toxicity index (PBTI) increased from 0.64 (±0.40) before drug infusion to 0.96 (±0.44) thereafter (P=0.0001). The highest displacement factor (DF) was calculated to be 2.8 (±0.6) at the end of drug infusion. Average total serum bilirubin concentrations decreased from a baseline value of 59.6 (±27.0) μmol/l to 55.2 (±27.1) μmol/l (P=0.026). Sixty minutes after the end of CRO infusion, RAC was 58.3 (±21.7) μmol/l, PBTI regained baseline, but DF was still 1.9 (±0.2). No adverse events were recorded. Our results demonstrate significant competitive interaction of CRO with bilirubin-albumin binding in vivo. Thus, cefriaxone should not be given to the neonate at risk of developing bilirubin encephalopathy.